Antonio Di Biagio
Experienced in Scrofula

Antonio Di Biagio

Genoa, IT 
Experienced in Scrofula
Genoa, IT 
OverviewLocationsClinical Research

Overview

Antonio Di Biagio practices in Genoa, Italy. Mr. Di Biagio is rated as an Experienced expert by MediFind in the treatment of Scrofula. His top areas of expertise are HIV/AIDS, Hepatitis, Hepatitis C, and Sepsis.

His clinical research consists of co-authoring 313 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Scrofula.

Gender
Male

Locations

Genoa, Italy
Other Locations
San Martino Di Venezze, Italy
Milan, Italy
Florence, Italy
Rome, Italy
Bari, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.
Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.
Enrollment Status: Completed
Publish Date: April 02, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among Virologically Suppressed, HIV-1 Infected Subjects With Mild or Asymptomatic EFV-related Neurocognitive or Neuropsychological Side Effects
A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among Virologically Suppressed, HIV-1 Infected Subjects With Mild or Asymptomatic EFV-related Neurocognitive or Neuropsychological Side Effects
Enrollment Status: Completed
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 1 Less Clinical Trial

313 Total Publications

Letter: Case Report: 12 Months Persisting Subcutaneous Nodule After Long-Acting Cabotegravir/Rilpivirine Administration.
Letter: Case Report: 12 Months Persisting Subcutaneous Nodule After Long-Acting Cabotegravir/Rilpivirine Administration.
Journal: AIDS patient care and STDs
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Di Biagio's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile